X

Trial Profile

A Single Arm Open-Label Study to Evaluate the Therapeutic Effects and Safety of a 6-Week Treatment Regimen of ALK4290 in Patients with Refractory Wet Age-Related Macular Degeneration (wAMD)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 04 Apr 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lazucirnon (Primary)
Indications Wet age-related macular degeneration
Focus Therapeutic Use
Sponsors Alkahest

Most Recent Events

29 Jul 2019 Primary endpoint has been met. (Best Corrected Visual Acuity (BCVA)), according to the Alkahest media release.
29 Jul 2019 According to an Alkahest media release, data from this trial was presented at the 2019 American Society of Retina Specialists Annual Meeting (ASRS) on July 27, 2019 in Chicago by Michael Stewart.
29 Jul 2019 Results published in the Alkahest media release

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com